%20--%3e%3csvg%20width='63.297821mm'%20height='39.29665mm'%20viewBox='0%200%2063.297821%2039.29665'%20version='1.1'%20id='svg8765'%20inkscape:version='1.1%20(c4e8f9ed74,%202021-05-24)'%20sodipodi:docname='OBALogoSingle2.svg'%20xmlns:inkscape='http://www.inkscape.org/namespaces/inkscape'%20xmlns:sodipodi='http://sodipodi.sourceforge.net/DTD/sodipodi-0.dtd'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:svg='http://www.w3.org/2000/svg'%3e%3csodipodi:namedview%20id='namedview8767'%20pagecolor='%23ffffff'%20bordercolor='%23666666'%20borderopacity='1.0'%20inkscape:pageshadow='2'%20inkscape:pageopacity='0.0'%20inkscape:pagecheckerboard='0'%20inkscape:document-units='mm'%20showgrid='false'%20fit-margin-top='0'%20fit-margin-left='0'%20fit-margin-right='0'%20fit-margin-bottom='0'%20inkscape:zoom='1.1759259'%20inkscape:cx='179.85827'%20inkscape:cy='102.04724'%20inkscape:window-width='1920'%20inkscape:window-height='972'%20inkscape:window-x='0'%20inkscape:window-y='27'%20inkscape:window-maximized='1'%20inkscape:current-layer='layer1'%20/%3e%3cdefs%20id='defs8762'%20/%3e%3cg%20inkscape:label='Layer%201'%20inkscape:groupmode='layer'%20id='layer1'%20transform='translate(-31.351095,-50.101677)'%3e%3cpath%20style='fill:none;stroke:%233584e4;stroke-width:3.965;stroke-linecap:square;stroke-linejoin:round;stroke-miterlimit:4;stroke-dasharray:none;stroke-opacity:1'%20d='m%2077.07508,77.78787%2014.84134,8.87817%20V%2052.83397%20L%2034.08359,86.5521%20V%2053.69366%20l%2015.27351,9.31107'%20id='path8388'%20sodipodi:nodetypes='cccccc'%20/%3e%3c/g%3e%3c/svg%3e)
Market Performance
Stock returned +10.0% over the past year, broadly in line with market conditions.Analyst Target
Analyst consensus price target: $2.00.What is CardioGenics Holdings Inc?
engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market.
CGNH · Verdict
Limited reward · high risk
CGNH has limited near-term tailwinds — cash flow and volatility weigh on the model output.
Based on 88% data coverage
CGNH · Verdict
What’s working & what to watch
Watchouts 5
- Cash flow5/100
Weak vs peers
- Volatility5/100
Weak vs peers
- Profitability10/100
0% return on equity
- Balance sheet36/100
Current ratio 0.03
- Growth41/100
Earnings +13.6% CAGR
Model-based scoring. For information only — not financial advice.
What is CardioGenics Holdings Inc?
engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market. Its products include QL Care Analyzer, which is a portable, stand-alone, and automated POC immunoanalyzer; a series of immunoassay tests to enhance the management of patients with cardiovascular diseases; and paramagnetic beads that are used as a solid surface in medical laboratories' immunoassay testing equipment. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 9.61K.
Financial Highlights
Investment Breakdown
Analysis
Reward: Moderate (38)The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are high — this profile reflects meaningful downside exposure.
For informational purposes only. Not financial advice.